VALNEVA : Prochains catalystes - pourquoi j'ai pris une louche speculative pour du MT

lemonphi

02 oct. 2026 •12:09

Q4 2026 (Near-Term)
FDA BLA Acceptance: Following positive Phase 3 VALOR trial data, the next key regulatory gate is the FDA's formal acceptance of Pfizer’s Biologics License Application (BLA). This will establish the official PDUFA action target date for the U.S. market.

November 12, 2026
Restructuring & Runway Health: Investors will evaluate the initial cost-reduction metrics of Valneva's active restructuring program. It must show positive P&L and cash-flow impacts to protect its €121.5M cash runway and eliminate intermediate equity dilution concerns.

Late 2026 / Early 2027
U.S. DoD Contract Renewal: Execution of an anticipated new U.S. Department of Defense supply contract for its Japanese encephalitis vaccine (IXIARO), driving H2 commercial sales visibility.

Mid-2027 (Within 12 months)
U.S. FDA Approval Decision: The anticipated regulatory action window for potential market authorization by the FDA based on the standard review timeline post-filing.

Q3 2027
EMA Approval Decision: Following the European Medicines Agency's (EMA) formal validation of the Marketing Authorization Application (MAA) on August 14, 2026, the regulatory review is projected to wrap up with an official marketing decision by Q3 2027.

H2 2027
Commercial Launch: Pending successful approvals, partner Pfizer is scheduled to initiate the global commercial launch, triggering tiered royalties (14% to 22%) and post-approval milestone inflows to Valneva.

Ongoing (2027)
Pipeline Progressions: Mid-stage pipeline catalysts include programmatic next steps to push the tetravalent Shigella candidate into Phase 3 development and finding a strategic funding partner for the Zika clinical asset.